The store will not work correctly when cookies are disabled.
4-(pyridin-3-ylmethylene)-2-(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one
ID: ALA1091767
PubChem CID: 6083135
Max Phase: Preclinical
Molecular Formula: C18H16N2O5
Molecular Weight: 340.34
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: COc1cc(C2=N/C(=C\c3cccnc3)C(=O)O2)cc(OC)c1OC
Standard InChI: InChI=1S/C18H16N2O5/c1-22-14-8-12(9-15(23-2)16(14)24-3)17-20-13(18(21)25-17)7-11-5-4-6-19-10-11/h4-10H,1-3H3/b13-7-
Standard InChI Key: CZYRBEYGZLMHBI-QPEQYQDCSA-N
Molfile:
RDKit 2D
25 27 0 0 0 0 0 0 0 0999 V2000
0.2251 -5.7919 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1904 -6.6185 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.8879 -7.0600 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6205 -6.6760 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6513 -5.8460 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9531 -5.4083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9840 -4.5838 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7134 -4.1984 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3852 -4.6839 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.0509 -4.1918 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7899 -3.4118 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.9649 -3.4170 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4771 -2.7517 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.8721 -4.1972 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2782 -4.9166 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1024 -4.9237 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.5215 -4.2121 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1104 -3.4919 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2875 -3.4883 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.5083 -5.6417 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.3333 -5.6488 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.3452 -4.2177 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.7625 -3.5060 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.5307 -2.7782 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.1214 -2.0618 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12 13 2 0
1 2 2 0
6 7 1 0
14 15 2 0
3 4 2 0
15 16 1 0
7 8 2 0
16 17 2 0
8 9 1 0
17 18 1 0
18 19 2 0
19 14 1 0
10 14 1 0
4 5 1 0
2 3 1 0
20 21 1 0
16 20 1 0
5 6 2 0
9 10 2 0
22 23 1 0
17 22 1 0
10 11 1 0
11 12 1 0
24 25 1 0
18 24 1 0
12 8 1 0
6 1 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 340.34 | Molecular Weight (Monoisotopic): 340.1059 | AlogP: 2.45 | #Rotatable Bonds: 5 |
Polar Surface Area: 79.24 | Molecular Species: NEUTRAL | HBA: 7 | HBD: ┄ |
#RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 4.68 | CX LogP: 2.15 | CX LogD: 2.15 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.61 | Np Likeness Score: -0.81 |
References
1. Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T.. (2010) Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening., 18 (7): [PMID:20206532] [10.1016/j.bmc.2010.02.018] |